Ironwood Pharmaceuticals, Inc. (IRWD)Healthcare | Drug Manufacturers - Specialty & Generic | Boston, United States | NasdaqGS
3.50 USD
-0.27
(-7.162%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 3.45 -0.05 (-0.050%) ⇩ (Oct. 16, 2026, 7:02 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 8:48 a.m. EDT
The investment case for Ironwood is currently paralyzed by a severe multi-year structural decline. Despite showing signs of operational recovery with 32% revenue growth and robust profitability margins, the stock has lost nearly 88% of its value over the last nine years, ending on four consecutive years of negative annual returns. This persistent price collapse suggests the market views the current earnings as insufficient to overcome deep-seated risks, likely related to the company's precarious balance sheet with negative book value and significant debt obligations. The recent guidance cut and FDA approval for LINZESS in children provide a glimmer of hope, but the relentless downward trajectory indicates investors remain deeply skeptical of the long-term outlook. Compounding this distress is a complete absence of dividend income, making the stock purely speculative. Furthermore, options activity confirms a bearish sentiment, with heavy put writing suggesting traders are betting on further declines rather than a rebound. Until the price trajectory stabilizes and demonstrates a sustained reversal of this decade-long decline, the risk-reward profile remains unfavorable. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.051874 |
| AutoETS | 0.054910 |
| AutoARIMA | 0.054911 |
| AutoTheta | 0.064149 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 7.35 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.096 |
| Excess Kurtosis | -0.65 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 2.387 |
| Market Cap | 578,339,840 |
| Trailing P/E | 4.49 |
| Forward P/E | 2.33 |
| Beta | 0.22 |
| Profit Margins | 33.36% |
| Website | https://ironwoodpharma.com |
As of Oct. 10, 2026, 8:48 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across all expirations, with the heaviest concentration in out-of-the-money strikes (e.g., $2.50). This distribution suggests a market consensus expecting further price weakness or a 'crash' scenario, while call activity remains sparse and concentrated only at the money or slightly out-of-the-money, indicating a lack of aggressive bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2727273 |
| Address1 | 100 Summer Street |
| Address2 | Suite 2300 |
| All Time High | 17.755444 |
| All Time Low | 0.53 |
| Ask | 4.05 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 1,920,800 |
| Average Daily Volume3 Month | 1,993,879 |
| Average Volume | 1,993,879 |
| Average Volume10Days | 1,920,800 |
| Beta | 0.22 |
| Bid | 3.05 |
| Bid Size | 1 |
| Board Risk | 1 |
| Book Value | -0.979 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.5 |
| Current Ratio | 6.063 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.73 |
| Day Low | 3.48 |
| Display Name | Ironwood Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,019,400 |
| Earnings Call Timestamp Start | 1,786,019,400 |
| Earnings Growth | 1.257 |
| Earnings Quarterly Growth | 1.173 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | 238,104,992 |
| Ebitda Margins | 0.6116 |
| Enterprise To Ebitda | 3.763 |
| Enterprise To Revenue | 2.302 |
| Enterprise Value | 896,078,784 |
| Eps Current Year | 1.21 |
| Eps Forward | 1.5 |
| Eps Trailing Twelve Months | 0.78 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 494 0480 |
| Fifty Day Average | 4.098 |
| Fifty Day Average Change | -0.59800005 |
| Fifty Day Average Change Percent | -0.14592485 |
| Fifty Two Week Change Percent | 127.27273 |
| Fifty Two Week High | 5.78 |
| Fifty Two Week High Change | -2.2800002 |
| Fifty Two Week High Change Percent | -0.3944637 |
| Fifty Two Week Low | 1.44 |
| Fifty Two Week Low Change | 2.06 |
| Fifty Two Week Low Change Percent | 1.4305555 |
| Fifty Two Week Range | 1.44 - 5.78 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,265,207,400,000 |
| Float Shares | 136,757,537 |
| Forward Eps | 1.5 |
| Forward P E | 2.3333333 |
| Free Cashflow | 121,834,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 100 |
| Fullday Change | -0.31999993 |
| Fullday Change Percent | -8.488062 |
| Fullday Price | 3.5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.77219003 |
| Gross Profits | 300,624,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03237 |
| Held Percent Institutions | 0.99084 |
| Implied Shares Outstanding | 165,239,947 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,554,163,200 |
| Last Split Factor | 1,194:1000 |
| Long Business Summary | Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. |
| Long Name | Ironwood Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 578,339,840 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_31498 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 129,868,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 704,748,373 |
| Number Of Analyst Opinions | 4 |
| Open | 3.7 |
| Operating Cashflow | 185,555,008 |
| Operating Margins | 0.70158 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 617 621 7722 |
| Post Market Change | -0.049999952 |
| Post Market Change Percent | -1.42857 |
| Post Market Price | 3.45 |
| Post Market Time | 1,792,191,765 |
| Previous Close | 3.77 |
| Price Eps Current Year | 2.892562 |
| Price Hint | 4 |
| Price To Book | -3.5750768 |
| Price To Sales Trailing12 Months | 1.4855281 |
| Profit Margins | 0.33358002 |
| Quick Ratio | 5.84 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.27 |
| Regular Market Change Percent | -7.1618 |
| Regular Market Day High | 3.73 |
| Regular Market Day Low | 3.48 |
| Regular Market Day Range | 3.48 - 3.73 |
| Regular Market Open | 3.7 |
| Regular Market Previous Close | 3.77 |
| Regular Market Price | 3.5 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 2,530,652 |
| Return On Assets | 0.47022998 |
| Revenue Growth | 0.326 |
| Revenue Per Share | 2.387 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 165,239,947 |
| Shares Percent Shares Out | 0.0942 |
| Shares Short | 15,567,942 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 17,654,677 |
| Short Name | Ironwood Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1029 |
| Short Ratio | 7.79 |
| Source Interval | 15 |
| State | MA |
| Symbol | IRWD |
| Target High Price | 10.0 |
| Target Low Price | 3.7 |
| Target Mean Price | 6.1 |
| Target Median Price | 5.35 |
| Total Cash | 79,127,000 |
| Total Cash Per Share | 0.479 |
| Total Debt | 396,865,984 |
| Total Revenue | 389,316,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.78 |
| Trailing P E | 4.4871798 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.01945 |
| Two Hundred Day Average Change | -0.5194502 |
| Two Hundred Day Average Change Percent | -0.12923414 |
| Type Disp | Equity |
| Volume | 2,530,652 |
| Website | https://ironwoodpharma.com |
| Zip | 2,110 |